Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study

References

• Cao W , ChenHD, YuYW, LiN, ChenWQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. (Engl.)134(7), 783–791 (2021).
   PubMed Web of Science ®Google Scholar
• Wu F , WangL, ZhouC. Lung cancer in China: current and prospect. Curr. Opin. Oncol.33(1), 40–46 (2021).
   PubMed Web of Science ®Google Scholar
• Chen P , LiuY, WenY, ZhouC. Non-small cell lung cancer in China. Cancer Commun. (Lond.)42(10), 937–970 (2022).
   PubMed Web of Science ®Google Scholar
• Imyanitov EN , IyevlevaAG, LevchenkoEV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit. Rev. Oncol. Hematol.157, doi:10.1016/j.critrevonc.2020.103194 (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Allemani C , MatsudaT, DiCarlo V et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet391(10125), 1023–1075 (2018).
   PubMed Web of Science ®Google Scholar
• Rusch VW , ChanskyK, KindlerHLet al. The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J. Thorac. Oncol.11(12),2112–2119 (2016).
   PubMed Web of Science ®Google Scholar
• Bagchi S , YuanR, EnglemanEG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance.Annu. Rev. Pathol.16, 223–249 (2021)
   PubMed Web of Science ®Google Scholar
• Dall’Olio FG , MarabelleA, CaramellaCet al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol.19(2), 75–90 (2022).
   PubMed Web of Science ®Google Scholar
• Shen G , ZhengF, RenD et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol.11(1), 120 (2018).
   PubMed Web of Science ®Google Scholar
• Lin B , SongX, YangD, BaiD, YaoY, LuN. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene654, 77–86 (2018).
   PubMed Web of Science ®Google Scholar
• Liang L , HuiK, HuC et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J. Exp. Clin. Cancer Res.38(1), 71 (2019).
   PubMedGoogle Scholar
• Lu J , ZhongH, ChuT et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur. Respir. J.53(3), doi:10.1183/13993003.01562-2018 (2019) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Song F , HuB, ChengJW et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell. Death Dis.11(7), 573 (2020).
   PubMed Web of Science ®Google Scholar
• Xu P , WangH, PanH, ChenJ, DengC. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway. Cancer Chemother. Pharmacol.89(2), 183–196 (2022).
   PubMed Web of Science ®Google Scholar
• Zhou AP , BaiY, SongY et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. Oncologist24(8), e702–e708 (2019).
   PubMed Web of Science ®Google Scholar
• Yang D , ChenF, GongD et al. Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib. Pediatr. Surg. Int.38(3), 465–472 (2022).
   PubMed Web of Science ®Google Scholar
• Genestreti G , GrossiF, GenovaCet al. Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Future Oncol.10(13), 2081–2096 (2014).
   PubMed Web of Science ®Google Scholar
• Galetta D , RossiA, ColucciG, GebbiaV. Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option?Oncology77(Suppl. 1), S113–S121 (2009).
   PubMedGoogle Scholar
• Han B , LiK, WangQet al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol.4(11), 1569–1575 (2018).
   PubMed Web of Science ®Google Scholar
• Zheng HR , JiangAM, GaoH et al. The efficacy and safety of anlotinib in extensive-stage small cell lung cancer: a multicenter real-world study. Cancer Manag. Res.14, 2273–2287 (2022).
   PubMed Web of Science ®Google Scholar
• Alshangiti A , ChandhokeG, EllisPM. Antiangiogenic therapies in non-small-cell lung cancer. Curr. Oncol.25(Suppl. 1), S45–S58 (2018).
   PubMedGoogle Scholar
• Cortot AB , Audigier-ValetteC, MolinierO et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: results of the IFCT-1103 ULTIMATE study. Eur. J. Cancer131, 27–36 (2020).
   PubMed Web of Science ®Google Scholar
• Rui M , LiH. Cost–effectiveness of osimertinib vs docetaxel-bevacizumab in third-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China. Clin. Ther.42(11), 2159–2170.e6 (2020).
   PubMed Web of Science ®Google Scholar
• Shen F , LiJ, LiuF et al. The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: a retrospective analysis. Fron. Oncol.13, doi:10.3389/fonc.2023.1095362 (2023) ( Epub ahead of print).
   Google Scholar
• Lv B , ChenJ, LiuXL. Anlotinib-induced hypertension: current concepts and future prospects. Curr. Pharm. Des.28(3), 216–224 (2022).
   PubMed Web of Science ®Google Scholar
• Sun Y , NiuW, DuF et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J. Hematol. Oncol.9(1), 105 (2016).
   PubMedGoogle Scholar